The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Kawalec P, Mikrut A, Lopuch S

Record Status
This is a systematic review that meets the criteria for inclusion on DARE.

Bibliographic details
Kawalec P, Mikrut A, Lopuch S. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes/Metabolism Research and Reviews 2014; 30(4): 269-283

PubMedID
24829965

DOI
10.1002/dmrr.2494

Original Paper URL

Indexing Status
Subject indexing assigned by NLM

MeSH
Administration, Oral; Diabetes Mellitus, Type 2 /drug therapy /immunology; Diarrhea /chemically induced /prevention & control; Dipeptidyl-Peptidase IV Inhibitors /administration & dosage /adverse effects /therapeutic use; Drug Therapy, Combination /adverse effects; Humans; Hypoglycemic Agents /administration & dosage /adverse effects /therapeutic use; Immunologic Factors /administration & dosage /adverse effects /therapeutic use; Membrane Transport Modulators /administration & dosage /adverse effects /therapeutic use; Metformin /administration & dosage /adverse effects /therapeutic use; Randomized Controlled Trials as Topic; Reproductive Tract Infections /epidemiology /immunology; Risk; Sodium-Glucose Transporter 2 /antagonists & inhibitors; Urinary Tract Infections /epidemiology /immunology

AccessionNumber
12014029722

Date bibliographic record published
28/08/2014